The DOI matches its Crossref record; 249 of the 254 references it cites were found in a registry or an index, and 3 are not checked yet; none of the 183 sources its claims cite is checked for support yet.
Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society
Open accessAbstract
BACKGROUND: Glucagon-like peptide 1 receptor agonists and combination medications (hereafter collectively referred to as GLP-1s) are shifting the treatment landscape for obesity. However, real-world challenges and limited clinician and public knowledge on nutritional and lifestyle interventions can limit GLP-1 efficacy, equitable results, and cost-effectiveness. OBJECTIVES: We aimed to identify pragmatic priorities for nutrition and other lifestyle interventions relevant to GLP-1 treatment of obesity for the practicing clinician. METHODS: An expert group comprising multiple clinical and research disciplines appraised the scientific literature, informed by expert knowledge and clinical experience, to identify and summarize relevant topics, priorities, and emerging directions. RESULTS: GLP-1s reduce body weight by 5% to 18% in trials, with modestly lower effects in real-world analyses, and multiple demonstrated clinical benefits. Challenges include side effects, especially gastrointestinal; nutritional deficiencies due to calorie reduction; muscle and bone loss; low long-term adherence with subsequent weight regain; and high costs with resulting low cost-effectiveness. Numerous practice guidelines recommend multicomponent, evidence-based nutritional and behavioral therapy for adults with obesity, but use of such therapies with GLP-1s is not widespread. Priorities to address this include: (a) patient-centered initiation of GLP-1s, including goals for weight reduction and health; (b) baseline screening, including usual dietary habits, emotional triggers, disordered eating, and relevant medical conditions; (c) comprehensive exam including muscle strength, function, and body composition assessment; (d) social determinants of health screening; (e) and lifestyle assessment including aerobic activity, strength training, sleep, mental stress, substance use, and social connections. During GLP-1 use, nutritional and medical management of gastrointestinal side effects is critical, as is navigating altered dietary preferences and intakes, preventing nutrient deficiencies, preserving muscle and bone mass through resistance training and appropriate diet, and complementary lifestyle interventions. Supportive strategies include group-based visits, registered dietitian nutritionist counseling, telehealth and digital platforms, and Food is Medicine interventions. Drug access, food and nutrition insecurity, and nutrition and culinary knowledge influence equitable obesity management with GLP-1s. Emerging areas for more study include dietary modulation of endogenous GLP-1, strategies to improve compliance, nutritional priorities for weight maintenance post-cessation, combination or staged intensive lifestyle management, and diagnostic criteria for clinical obesity. CONCLUSIONS: Evidence-based nutritional and lifestyle strategies play a pivotal role to address key challenges around GLP-1 treatment of obesity, making clinicians more effective in advancing their patients' health.
Checked 2026-10-06 · 3 references not checked yet
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This joint Advisory from four clinical societies summarizes pragmatic nutritional and lifestyle priorities to support GLP-1 therapy for obesity, emphasizing screening, GI side-effect management, nutrient adequacy, muscle/bone preservation, and equitable implementation. It concludes that structured nutrition and behavioral care before, during, and after GLP-1 use can mitigate key challenges and improve long-term outcomes.
Key findings
- GLP-1s produce placebo-adjusted weight reduction of 5% to 18% in trials, with lower real-world effects (e.g., about 8% with diabetes and 11% without diabetes at 60 weeks with semaglutide 2.4 mg/d); discontinuation is high (e.g., 50%–67% at 1 year and 85% at 2 years in some real-world data).
- Common GI side effects include nausea (25%–44%), diarrhea (19%–30%), vomiting (8%–24%), constipation (17%–24%), and abdominal pain (9%–20%); caloric intake falls by 16%–39%, raising risk of inadequate intakes of iron, calcium, magnesium, zinc, and vitamins A, D, E, K, B1, B12, and C.
- Rapid weight loss can cause muscle and bone loss: in STEP 1, of a mean 13.6-kg weight reduction, 8.3 kg (62%) was fat mass and 5.3 kg (38%) was lean body mass, corresponding to about 20% of total weight reduction as muscle loss; structured resistance training at least 3 times weekly plus at least 150 min/week of moderate aerobic exercise is recommended to help preserve muscle and bone.
- Costs are high: US list prices are about $12,000–$16,000 per year, discounted to about $7,000–$8,000; nonindustry cost-effectiveness analyses report net costs per quality-adjusted life year of $237,000–$483,000, exceeding common thresholds.
Methods
- An expert group comprising multiple clinical and research disciplines appraised the scientific literature, informed by expert knowledge and clinical experience, to identify and summarize relevant topics, priorities, and emerging directions.
- The paper is a narrative joint Advisory, not a systematic review or meta-analysis; it synthesizes evidence and provides practice guidance, tables, and a figure for clinicians.
- No primary data collection or formal quantitative synthesis is reported.
Limitations
- The paper states that peer-reviewed evidence has not kept pace with clinical and public interest in GLP-1s, that some guidance is based on limited available evidence and expert opinion, and that specific nutritional behaviors for weight maintenance after GLP-1 cessation have not been rigorously studied in controlled trials.
- It also notes limited direct evidence on GLP-1 use with or without registered dietitian nutritionist–provided medical nutrition therapy, and lack of standardization in how “intensive” lifestyle intervention is defined or implemented across trials.
- Evident from the text: as a narrative expert Advisory, it does not describe a systematic search strategy, formal risk-of-bias assessment, or evidence-grading process, so recommendations may reflect expert consensus where data are sparse.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 183 cited sources checked · 0 supported · 0 flagged
None of the sources cited for this claim have been checked yet.
In the paper
“Notably, this has been observed even with accompanying use of conventional nutritional counseling and/or behavioral therapy [18,19].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Efficacy
What the sources say
- Not checked yetcites [18] Aronne, 2024, Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial, JAMA source
- Not checked yetcites [19] Rubino, 2021, Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial, JAMA source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“Higher doses are more likely to provoke these adverse symptoms, indicating a dose-dependent relationship [40].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Side effects
What the sources say
- Not checked yetcites [40] Gorgojo-Martinez, 2022, Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus, J Clin Med source
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“In the trials, GI symptoms rarely led to discontinuation, with <10% of participants stopping therapy due to GI issues [49].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Side effects
What the sources say
- Not checked yetcites [49] Tomlinson, 2016, Investigational glucagon-like peptide-1 agonists for the treatment of obesity, Expert Opin Investig Drugs source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“GLP-1s activate several brain regions responsible for weight regulation, appetite, and nausea [51].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Side effects
What the sources say
- Not checked yetcites [51] Baggio, 2014, Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight, J Clin Invest source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“Combining GLP-1s with metformin does not appear to worsen GI side effects, despite metformin’s association with similar symptoms [50].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Side effects
What the sources say
- Not checked yetcites [50] Klein, 2024, Occurrence of gastrointestinal adverse events upon GLP-1 receptor agonist initiation with concomitant metformin use: a post hoc analysis of LEADER, STEP 2, SUSTAIN-6, and PIONEER 6, Diabetes Care source
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“Occasionally, GLP-1s affect intestinal motility or secretions, contributing to diarrhea [46].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Side effects
What the sources say
- Not checked yetcites [46] Sun, 2015, Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis, Diabetes Technol Ther source
Strength:plain· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“When GLP-1 use is continued, weight reduction is sustained for at least 4 y in controlled and observational studies [16,17].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Efficacy
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“When GLP-1s are discontinued, weight regain is common—with up to two-thirds of the lost weight regained within 1 y [[18], [19], [20]].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Efficacy
What the sources say
- Not checked yetcites [18] Aronne, 2024, Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial, JAMA source
- Not checked yetcites [19] Rubino, 2021, Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial, JAMA source
- Not checked yetcites [20] Wilding, 2022, Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension, Diabetes Obes Metab source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“In the original phase 3 randomized trials for obesity, average weight reduction compared to placebo has ranged from 5.3% to 17.8% after 56 to 72 wk (Table 1), with improvements in several obesity-related risks and complications [[13], [14], [15]].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Efficacy
What the sources say
- Not checked yetcites [13] Pi-Sunyer, 2015, A randomized, controlled trial of 3.0 mg of liraglutide in weight management, N Engl J Med source
- Not checked yetcites [14] Wilding, 2021, Once-weekly semaglutide in adults with overweight or obesity, N Engl J Med source
- Not checked yetcites [15] Jastreboff, 2022, Tirzepatide once weekly for the treatment of obesity, N Engl J Med source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“Rapid weight reduction from (but not limited to) GLP-1 use frequently leads to loss of both fat and muscle mass [62,63].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Muscle and bone loss
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- It may state two separate claims as one. 72
- Probably not a substantial claim. 20
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although certain side effects have been reported more commonly with semaglutide than with tirzepatide, trial data suggest that such differences may be a reflection of variation in background (i.e., placebo group) rates in the enrolled trial populations, with the proportional increase in many side effects when compared to placebo being similar for the 2 agents (Table 2).”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Side effects
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“In multivariate analyses, factors predicting larger responses with tirzepatide include female sex (2.4 higher odds of achieving a 20% weight reduction), lower baseline hemoglobin A1c (1.62 higher odds), no diagnosed hypertension (1.35 higher odds), and lower ALT (1.17 higher odds) [21];”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Efficacy
What the sources say
- Not checked yetcites [21] Srinath, 2023, SAT660 Predictors of achieving body weight reduction ≥20% with tirzepatide in people with overweight or obesity in SURMOUNT-1, J Endocr Soc
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Side effects are relatively common but usually not severe. These are more likely to occur within the first weeks of initiation of therapy and with dose escalation. Side effects tend to decrease in frequency and severity with continuation of a stable dose [40].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Side effects
What the sources say
- Not checked yetcites [40] Gorgojo-Martinez, 2022, Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus, J Clin Med source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“In real-world practice, the efficacy for weight reduction is often lower, for example, about 8% for individuals with diabetes and 11% for individuals without diabetes at 60 wk with semaglutide 2.4 mg/d [4].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Efficacy
What the sources say
- Not checked yetcites [4] Little, 2023
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although these findings describe the average response, individual responses can vary widely, highlighting the complexity of obesity as a disease. Some people experience minimal weight reduction with GLP-1s, whereas others have robust weight reductions of ≥30%.”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Efficacy
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“For example, hemoglobin A1c reduction can occur without weight change, and reduced risk of cardiovascular events appears to emerge before substantial weight reduction [38,39].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Efficacy
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“and in univariate (crude) analyses with semaglutide, female sex (48% greater weight loss in kilograms), younger age (24% greater for age <55 vs. ≥75 y), and higher baseline BMI (23% greater for ≥40 vs. <30 kg/m2) [16].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Efficacy
What the sources say
- Not checked yetcites [16] Ryan, 2024, Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial, Nat Med source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“GLP-1s delay gastric emptying, leading to bloating, fullness, and nausea [43].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Side effects
What the sources say
- Not checked yetcites [43] Filippatos, 2014, Adverse effects of GLP-1 receptor agonists, Rev Diabet Stud source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although many of these benefits are weight-dependent, others appear at least partly weight-independent.”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Efficacy
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“GI side effects are most frequent and include nausea (25%–44%), diarrhea (19%–30%), vomiting (8%–24%), constipation (17%–24%), and abdominal pain (9%–20%) [[41], [42], [43], [44], [45], [46]].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Side effects
What the sources say
- Not checked yetcites [41] Nordisk, 2023
- Not checked yetcites [42] 2023
- Not checked yetcites [43] Filippatos, 2014, Adverse effects of GLP-1 receptor agonists, Rev Diabet Stud source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Real-world experience has largely mirrored these trial data, with GI issues (nausea, diarrhea, vomiting, constipation) being the most frequently reported side effects [47,48].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Side effects
What the sources say
- Not checked yetcites [47] Liu, 2022, Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database, Front Endocrinol (Lausanne) source
- Not checked yetcites [48] Shetty, 2022, Adverse drug reactions of GLP-1 agonists: a systematic review of case reports, Diabetes Metab Syndr source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Weight reduction that is substantial (≥14%) and rapid (over 3–4 mo) is associated with significant bone loss [71], whereas more moderate and slower weight reduction may better preserve bone mass [72].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Muscle and bone loss
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Ophthalmic complications have been rarely reported, which could relate to direct toxicity or rapid GLP-1-correction of hyperglycemia [52].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Side effects
What the sources say
- Not checked yetcites [52] Katz, 2025, Ophthalmic complications associated with the antidiabetic drugs semaglutide and tirzepatide, JAMA Ophthalmol source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Bone loss is influenced by initial body weight, age, sex, physical activity, extent of energy restriction and protein intake, and rate of weight reduction, with older individuals and females experiencing greater bone loss [71].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Muscle and bone loss
What the sources say
- Not checked yetcites [71] Shapses, 2006, Bone, body weight, and weight reduction: what are the concerns?, J Nutr source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the absence of structured nutrition and exercise efforts, loss of muscle and bone may be exacerbated by intermittent use of GLP-1s and weight regain or “weight cycling,” increasing risk of sarcopenic obesity.”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Muscle and bone loss
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Signs of frank nutrient deficiency include fatigue beyond expected levels, excessive hair loss, skin flakiness or itching, muscle weakness, poor wound healing, and unusual bruising [59].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Nutritional deficiencies
What the sources say
- Not checked yetcites [59] Raymond, 2022
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Several studies have estimated the cost-effectiveness of GLP-1s for obesity from a healthcare perspective, considering costs for screening and treatment against savings from improved weight and health outcomes and corresponding long-term reductions in healthcare utilization, including downstream accumulated health benefits. All have found that GLP-1 treatment costs exceed healthcare savings.”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Adherence and costs
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“These reductions in fat mass, lean body mass, and muscle mass correlate with the degree of body weight reduction and are similar to those documented with other obesity therapies that achieve large weight reductions, such as bariatric surgery and very low-calorie restricted diets [65].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Muscle and bone loss
What the sources say
- Not checked yetcites [65] Nuijten, 2022, The magnitude and progress of lean body mass, fat-free mass, and skeletal muscle mass loss following bariatric surgery: a systematic review and meta-analysis, Obes Rev source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Medicare does not currently cover GLP-1s for obesity, but recently announced that they will be among the drug classes which the federal government will aim to negotiate in 2025; average price reductions in prior negotiations for other drug classes have ranged from 38% to 79% from the original list price [80].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Adherence and costs
What the sources say
- Not checked yetcites [80] 2025
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Local and regional compounding pharmacies also directly manufacture GLP-1s, with gray literature prices from ∼$1800 to $3000 per year [81]. However, this is not regulated by the FDA for safety or efficacy; and recent FDA guidance has aimed to eliminate this production.”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Adherence and costs
What the sources say
- Not checked yetcites [81] Landi
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Discontinuation is associated with older age (≥65 y), poor weight response, and moderate or severe GI side effects [74].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Adherence and costs
What the sources say
- Not checked yetcites [74] Rodriguez, 2025, Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity, JAMA Netw Open source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“GI side effects may further compromise nutrient absorption and exacerbate preceding or new risk of nutrient insufficiency.”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Nutritional deficiencies
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Rare cases of suicidality have been reported, although preliminary evaluation using the FDA Adverse Reporting System, post hoc analysis of the STEP clinical trials, and 1 large cohort study have not confirmed any definitive link; the FDA and European Agencies are monitoring potential risk [[53], [54], [55]].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Side effects
What the sources say
- Not checked yetcites [53]
- Not checked yetcites [54] Wadden, 2024, Psychiatric safety of semaglutide for weight management in people without known major psychopathology: post hoc analysis of the STEP 1, 2, 3, and 5 trials, JAMA Intern Med source
- Not checked yetcites [55] Shapiro, 2025, Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study, BMJ source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Rare side effects include gallbladder disease, pancreatitis, acute kidney injury (typically related to hypovolemia), hypersensitivity reactions, and gastroparesis [12,41].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Side effects
What the sources say
- Not checked yetcites [12] 2024
- Not checked yetcites [41] Nordisk, 2023
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“According to the USPSTF, the evidence supports referring all adults with obesity to intensive, multicomponent behavioral interventions for both weight reduction and weight maintenance.”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Guidelines and Practice for Nutrition and Lifestyle Counseling for Obesity > Current guidelines
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“In addition, although health coaching is theoretically reimbursable by some private insurers, employee wellness benefits, Medicare Advantage plans, and state Medicaid programs, the lack of approval of category I Current Procedural Terminology codes for health coaching by the American Medical Association remains a barrier to reimbursement [107,108].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Guidelines and Practice for Nutrition and Lifestyle Counseling for Obesity > Current practice
What the sources say
- Not checked yetcites [107]
- Not checked yetcites [108]
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Multiple studies demonstrate beneficial effects on food cravings and disordered eating. This includes reduced food preoccupation or “food noise”, reduced emotional eating, less external eating (i.e., eating that responds to external triggers, irrespective of satiety), and fewer binge eating episodes [56,149].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Navigation of dietary preferences and intakes
What the sources say
- Not checked yetcites [56] Christensen, 2024, Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: a narrative review and discussion of research needs, Obes Pillars
- Not checked yetcites [149] Tronieri, 2020, Effects of liraglutide on appetite, food preoccupation, and food liking: results of a randomized controlled trial, Int. J. Obes. (Lond.) source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Serial studies from the US and Europe suggest that energy expenditure from physical activity increased between 1981 and 2017, during the onset of the obesity epidemic, while basal metabolic expenditure declined, implicating other factors such as dietary composition that impact metabolic rate [86].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Guidelines and Practice for Nutrition and Lifestyle Counseling for Obesity
What the sources say
- Not checked yetcites [86] Speakman, 2023, Total daily energy expenditure has declined over the past three decades due to declining basal expenditure, not reduced activity expenditure, Nature Metabolism source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Although authoritative health and medical entities recommend comprehensive lifestyle modification as part of the treatment plan for obesity, the use of such therapies before or to support GLP-1 use is not widespread in practice.”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Guidelines and Practice for Nutrition and Lifestyle Counseling for Obesity > Current practice
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“These high costs, lower adherence in practice, and frequent weight regain after discontinuation, each highlight the importance of complementary nutritional and lifestyle counseling to help maximize overall efficacy and cost-effectiveness [84].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Adherence and costs
What the sources say
- Not checked yetcites [84] Kim, 2024, Balancing innovation and affordability in anti-obesity medications: the role of an alternative weight-maintenance program, Health Aff Sch
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In this writing group’s experience, we observe that many individuals prescribed GLP-1s have not received meaningful nutrition or other lifestyle guidance preceding, accompanying, or (if the drug is stopped) after the therapy.”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Guidelines and Practice for Nutrition and Lifestyle Counseling for Obesity > Current practice
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✗ Checkable: fails✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. It may be too vague to check against evidence. The paper may give no reason why it holds.
In the paper
“GLP-1s meaningfully impact total energy intake and food preferences through multiple mechanisms—an active area of investigation—including peripherally in the gut, centrally in multiple brain regions, and through diet-microbiome–brain interactions [142].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Navigation of dietary preferences and intakes
What the sources say
- Not checked yetcites [142] Chen, 2021, GLP-1 suppresses feeding behaviors and modulates neuronal electrophysiological properties in multiple brain regions, Front. Mol. Neurosci. source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Dehydration from severe nausea, vomiting, or diarrhea can cause acute kidney injury, with or without existing kidney disease [140], as well as heart palpitations, so efforts should be made to prevent dehydration.”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Management of GI side effects
What the sources say
- Not checked yetcites [140] Bradshaw, 2018, Acute kidney injury due to diarrheal illness requiring hospitalization: data from the National Inpatient Sample, J. Gen. Intern. Med. source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“preclinical studies suggest that GLP-1 receptor activation may modulate inflammatory and immune responses that affect the brain [146].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Navigation of dietary preferences and intakes
What the sources say
- Not checked yetcites [146] Diz-Chaves, 2022, Anti-inflammatory effects of GLP-1 receptor activation in the brain in neurodegenerative diseases, Int. J. Mol. Sci. source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“The high and rising prevalence of obesity globally is often attributed to poor dietary patterns and insufficient physical activity, which are often related to behaviors learned early in life and developed over time as well as structural barriers to good lifestyle [85].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Guidelines and Practice for Nutrition and Lifestyle Counseling for Obesity
What the sources say
- Not checked yetcites [85] 2012
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“GLP-1s reduce energy intake by 16%–39% compared with placebo, related to changes in cravings, hunger, and fullness [56,147,148].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Navigation of dietary preferences and intakes
What the sources say
- Not checked yetcites [56] Christensen, 2024, Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: a narrative review and discussion of research needs, Obes Pillars
- Not checked yetcites [147] Wharton, 2023, Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5, Obesity, Silver Spring, Md) source
- Not checked yetcites [148] Heise, 2023, Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes, Diabetes Care source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“For example, the Diabetes Prevention Program is known to reduce the risk of progression to diabetes and is covered by major payers, but has not been meaningfully scaled due to regulatory and implementation barriers [105,106].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Guidelines and Practice for Nutrition and Lifestyle Counseling for Obesity > Current practice
What the sources say
- Not checked yetcites [105] Halley, 2020, Barriers and facilitators to real-world implementation of the Diabetes Prevention Program in large healthcare systems: Lifestyle coach perspectives, J. Gen. Intern. Med. source
- Not checked yetcites [106] Rawal, 2024, Facilitators and barriers to implementing the Diabetes Prevention Program in rural church settings: a qualitative study using the Consolidated Framework for Implementation Research, J. Rural Health
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“As GLP-1s are becoming more commonly prescribed for obesity and other health conditions by providers across multiple disciplines, there is growing concern for the continued lack of formal medical training in nutrition and obesity and the paucity of basic knowledge and competencies to provide nutrition counseling [111,112].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Guidelines and Practice for Nutrition and Lifestyle Counseling for Obesity > Current practice
What the sources say
- Not checked yetcites [111] Devries, 2014, A deficiency of nutrition education in medical training, Am. J. Med. source
- Not checked yetcites [112] Harkin, 2019, Physicians' dietary knowledge, attitudes, and counseling practices: the experience of a single health care center at changing the landscape for dietary education, Am. J. Lifestyle Med. source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Various dietary patterns have been used with success, with adherence to counseling visits and the selected diet often being the important factors in determining outcomes [101].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Guidelines and Practice for Nutrition and Lifestyle Counseling for Obesity > Current guidelines
What the sources say
- Not checked yetcites [101] Sacks, 2009, Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates, N. Engl. J. Med. source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“with low cost-effectiveness related to plateauing of weight benefits but continued high costs of treatment, as well as weight regain following any cessation of use.”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Overview of Efficacy, Side Effects, and Key Challenges > Adherence and costs
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Foods high in protein or fat can further slow gastric emptying, which can promote weight reduction and metabolism but also worsen constipation, potentially requiring temporary limitation of these foods [141].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Management of GI side effects
What the sources say
- Not checked yetcites [141] Gentinetta, 2024, Dietary recommendations for the management of gastrointestinal symptoms in patients treated with GLP-1 receptor agonist, Diabetes Metab. Syndr. Obes. source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Smaller, more frequent meals and avoiding fatty or high fiber foods during the first few days of treatment can help alleviate symptoms [45].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Management of GI side effects
What the sources say
- Not checked yetcites [45] Wharton, 2022, Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice, Postgrad Med source
Strength:plain· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Specific nutrient goals can vary by age, sex, and life stage (e.g., infancy, childhood, adolescence, pregnancy, lactation, older adulthood) [102] as well as comorbidities or clinical conditions.”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Guidelines and Practice for Nutrition and Lifestyle Counseling for Obesity > Current guidelines
What the sources say
- Not checked yetcites [102] National Institutes of Health. Nutrient Recommendations: Dietary Reference Intakes (DRI). National Institutes of Health.
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Excess dietary protein, above muscle needs for repair or growth, can be converted to fat by the liver and increase visceral adiposity [167].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Preservation of muscle and bone mass
What the sources say
- Not checked yetcites [167] Charidemou, 2019, A randomized 3-way crossover study indicates that high-protein feeding induces de novo lipogenesis in healthy humans, JCI Insight source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A structured, comprehensive nutrition and lifestyle program could help augment the weight reduction efficacy of GLP-1s, although findings have been mixed.”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Maximization of weight reduction
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Aerobic and resistance training exercises also improve insulin sensitivity, vascular function, and oxidative stress, critical for long-term cardiometabolic health [172].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Preservation of muscle and bone mass
What the sources say
- Not checked yetcites [172] Liu, 2023, Liraglutide and exercise synergistically attenuate vascular inflammation and enhance metabolic insulin action in early diet-induced obesity, Diabetes source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Mental stress should be addressed among individuals with obesity, as chronic stress may promote obesity development through the sympathetic nervous system and hypothalamic-pituitary-adrenal axis activation that elevates cortisol levels, interferes with insulin sensitivity, promotes energy storage, and creates food cravings for ultraprocessed “comfort foods” [189]”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Other supportive lifestyle interventions
What the sources say
- Not checked yetcites [189] Scott, 2012, Effects of chronic social stress on obesity, Curr. Obes. Rep. source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“In a recent randomized trial, one year of combined GLP-1 therapy with exercise training preserved bone mineral density, while GLP-1 therapy alone decreased bone mineral density [170].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Preservation of muscle and bone mass
What the sources say
- Not checked yetcites [170] Jensen, 2024, Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial, JAMA Netw. Open source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All these technologies monitor muscle mass but not muscle health, quality, or function.”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Preservation of muscle and bone mass
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
In the paper
“Poor sleep is associated with insulin resistance, increased hunger, and weight gain, which might reduce some benefits of GLP-1s [183].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Other supportive lifestyle interventions
What the sources say
- Not checked yetcites [183] Beccuti, 2011, Sleep and obesity, Curr. Opin. Clin. Nutr. Metab. Care
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, these influences are less rigorously documented, with varying study results.”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Navigation of dietary preferences and intakes
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Estimated fat-free mass may be best for determining protein needs, although there is still no consensus on the optimal approach.”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Preservation of muscle and bone mass
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Among food sources, plant sources (e.g., beans, peas, lentils, whole grains), dairy, seafood, eggs, and lean poultry should generally be encouraged based on their links to general health, with red and processed meats considered in moderation or minimized given links to type 2 diabetes, cardiovascular disease, and colorectal cancer in general populations [60].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Preservation of muscle and bone mass
What the sources say
- Not checked yetcites [60] 2024
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
In the paper
“A protein intake of 1.5 g per kilogram of lean body mass (FFM) per day is considered more accurate but requires body composition data for precise calculation [166].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Preservation of muscle and bone mass
What the sources say
- Not checked yetcites [166] Grosicki, 2024, Sculpting success: the importance of diet and physical activity to support skeletal muscle health during weight loss with new generation anti-obesity medications, Curr. Dev. Nutr. source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“GLP-1s may act both centrally and peripherally to reduce these downstream impacts of chronic stress and obesity and alter food reward pathways in positive ways [132].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Other supportive lifestyle interventions
What the sources say
- Not checked yetcites [132] Guerrero-Hreins, 2021, The therapeutic potential of GLP-1 analogues for stress-related eating and role of GLP-1 in stress, emotion and mood: a review, Prog. Neuropsychopharmacol. Biol. Psychiatry source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Different studies suggest reduced cravings for savory foods and high-fat foods [150,151]; sweet, savory, or dairy foods [144]; salty, spicy, starchy, or dairy foods [147]; and sweets, carbohydrates, starches, and fast-food fats [154].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Navigation of dietary preferences and intakes
What the sources say
- Not checked yetcites [150] Blundell, 2017, Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity, Diabetes Obes. Metab. source
- Not checked yetcites [151] Gibbons, 2021, Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes, Diabetes Obes. Metab. source
- Not checked yetcites [144] Bettadapura, 2024, Changes in food preferences and ingestive behaviors after glucagon-like peptide-1 analog treatment: techniques and opportunities, Int. J. Obes. (Lond.)
- Not checked yetcites [147] Wharton, 2023, Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5, Obesity, Silver Spring, Md) source
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A challenge in interpreting the impact of the lifestyle strategies in these trials is lack of standardization on how “intensive” lifestyle intervention is defined or implemented.”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Maximization of weight reduction
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
None of the sources cited for this claim have been checked yet.
In the paper
“Higher targets, such as 1.2–1.6 g/kg/d, have also been proposed during active weight reduction [162,163].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Preservation of muscle and bone mass
What the sources say
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Protein-rich foods can be consumed first in a meal to increase the likelihood of sufficient consumption.”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Preservation of muscle and bone mass
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“Enhanced mindfulness may also help individuals cope with GLP-1 side effects [192].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Other supportive lifestyle interventions
What the sources say
- Not checked yetcites [192] Greeson, 2019, Mindfulness and physical disease: a concise review, Curr. Opin. Psychol. source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Still, some are less sensitive to change (e.g., handgrip strength) or not feasible to conduct in a clinical setting (e.g., quadricep isometric strength).”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Preservation of muscle and bone mass
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Small, frequent meals may be effective when hunger and food interest are low [58].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Prevention and mitigation of nutrient deficiencies
What the sources say
- Not checked yetcites [58] Almandoz, 2024, Nutritional considerations with antiobesity medications, Obesity (Silver Spring) source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Sit-to-stand, stair climb, and timed-up-and-go measures can be helpful in older adults, but these measures may be less able to detect changes in younger individuals.”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Preservation of muscle and bone mass
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
In the paper
“Protein intake in adults should not fall below 0.4–0.5 g/kg/d, as this can lead to muscle atrophy and functional impairments, whereas prolonged intake at or above 2 g/kg/d should be avoided due to potential adverse health effects [165].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Preservation of muscle and bone mass
What the sources say
- Not checked yetcites [165] Heymsfield, 2024, Guidance on energy and macronutrients across the life span, N. Engl. J. Med. source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Alternatively, setting an absolute protein target of 80–120 g/d, or 16%–24% energy on a 2000 kcal/d diet, may enhance adherence while ensuring adequate intake.”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Preservation of muscle and bone mass
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
In the paper
“In a study of ∼1.2 million commercially insured U.S. individuals with diabetes from 2015 to 2019, lower GLP-1 use was seen among Asian, Black, and Hispanic, compared with White, individuals and among those living in lower versus higher income households [237].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > GLP-1s and Health Equity > GLP-1 access
What the sources say
- Not checked yetcites [237] Eberly, 2021, Racial, ethnic, and socioeconomic inequities in glucagon-like peptide-1 receptor agonist use among patients with diabetes in the US, JAMA Health Forum source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Although limited direct evidence has evaluated use of GLP-1s with or without RDN-provided MNT, the SCALE [13], STEP 1 [14], SURMOUNT [15], and STEP 3 [178] trials each demonstrated substantial weight reduction by combining GLP-1s with regular counseling sessions by RDNs or other qualified healthcare professionals (such lifestyle support was also provided to the placebo group in each trial).”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Behavior Change and Implementation Supports > Registered dietitian nutritionists
What the sources say
- Not checked yetcites [13] Pi-Sunyer, 2015, A randomized, controlled trial of 3.0 mg of liraglutide in weight management, N Engl J Med source
- Not checked yetcites [14] Wilding, 2021, Once-weekly semaglutide in adults with overweight or obesity, N Engl J Med source
- Not checked yetcites [15] Jastreboff, 2022, Tirzepatide once weekly for the treatment of obesity, N Engl J Med source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“These tools can help address barriers posed by in-person visits, enhance patient engagement, and promote adherence to nutritional and lifestyle recommendations [[226], [227], [228], [229]].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Behavior Change and Implementation Supports > Telehealth and digital platforms
What the sources say
- Not checked yetcites [226] Ezeamii, 2024, Revolutionizing healthcare: how telemedicine is improving patient outcomes and expanding access to care, Cureus
- Not checked yetcites [227] Kelly, 2016, Telehealth methods to deliver dietary interventions in adults with chronic disease: a systematic review and meta-analysis, Am. J. Clin. Nutr. source
- Not checked yetcites [228] Bashshur, 2014, The empirical foundations of telemedicine interventions for chronic disease management, Telemed. e-Health source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“One retrospective study identified higher likelihood of prescribing obesity management medication as well as higher relative weight reduction with GMVs versus individual medical visits [211].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Behavior Change and Implementation Supports > Group-based visits
What the sources say
- Not checked yetcites [211] Shibuya, 2020, Association between shared medical appointments and weight loss outcomes and anti-obesity medication use in patients with obesity, Obes. Sci. Pract. source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Team-based care, including registered dietitian nutritionists (RDNs), exercise physiologists, and health coaches, can be very helpful [204] but is not always available to clinicians or individuals depending on health system circumstances and payer policies.”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Other supportive lifestyle interventions
What the sources say
- Not checked yetcites [204] Kane, 2024, Opportunities for general internal medicine to promote equity in obesity care, J. Gen. Intern. Med.
Strength:plain· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Long periods of fasting without sufficient protein intake or dietary variety can lead to nutritional inadequacy, clinical nutrient deficiencies, loss of fat-free mass, and reduced resting energy expenditure [297].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Future Directions > Use of specific dietary patterns
What the sources say
- Not checked yetcites [297] Agagunduz, 2021, Effect of intermittent fasting (18/6) on energy expenditure, nutritional status, and body composition in healthy adults, Evid. Based Complement. Alternat. Med. source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Pairing GLP-1 use with RDN dietary counseling should support medication adherence, help prevent or manage GI side effects (particularly during medication initiation and dose increases), promote adequacy of nutrient intake, and support engagement in other behaviors (e.g., regular physical activity, adequate sleep, goal-setting) that enhance long-term weight management and overall health.”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Behavior Change and Implementation Supports > Registered dietitian nutritionists
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
In the paper
“Compared to conventional visits, GMVs have demonstrated improved dietary habits, improved sleep, greater patient satisfaction, better glycemic and blood pressure control among individuals with diabetes mellitus, modest but significant weight reduction improvement, particularly in females and older adults, and reduced healthcare costs [[207], [208], [209], [210]].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Behavior Change and Implementation Supports > Group-based visits
What the sources say
- Not checked yetcites [[207], [208], [209], [210]]
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Nutrient supplementation with fiber, resistant starch, and unsaturated fats are the most studied supplements in both animal studies and small-scale human trials—often showing increased circulating GLP-1 concentrations and associated metabolic improvements [269].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Future Directions > Dietary modulation of GLP-1 release and action
What the sources say
- Not checked yetcites [269] Rui, 2013, Brain regulation of energy balance and body weight, Rev. Endocr. Metab. Disord. source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“RDNs who provide MNT for obesity care can follow evidence-based practice guidelines [220] and earn a board-certified specialist credential in obesity and weight management [221].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Behavior Change and Implementation Supports > Registered dietitian nutritionists
What the sources say
- Not checked yetcites [220] Morgan-Bathke, 2023, Medical nutrition therapy interventions provided by dietitians for adult overweight and obesity management: an Academy of Nutrition and Dietetics evidence-based practice guideline, J. Acad. Nutr. Diet. source
- Not checked yetcites [221]
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Medicare covers MNT only for individuals with diagnoses of diabetes, chronic kidney disease, and 36 months post-kidney transplant, and for only 3 h during the first year of referral and 2 h annually thereafter [223].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Behavior Change and Implementation Supports > Registered dietitian nutritionists
What the sources say
- Not checked yetcites [223] US Congress. United States Code: Social Security Act, U.S.C. § 1395x: Definitions. From Title 42 -The Public Health and Welfare. Chapter 7-Social Security. Subchapter XVII-Health Insurance for Aged And Disabled. Part E-Miscellaneous Provisions.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“In both traditional fee-for-service and value-based health delivery models, GMVs can increase access to healthcare professionals, promote in-depth, unrushed medical visits, promote social connection and support, and improve individual engagement and outcomes [206].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Behavior Change and Implementation Supports > Group-based visits
What the sources say
- Not checked yetcites [206] Lacagnina, 2021, Lifestyle medicine shared medical appointments, Am. J. Lifestyle Med. source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“A recent expert group reviewed the utility of BMI-based measures for assessing individual health and concluded that these can misclassify (both underestimate and overestimate) adiposity—and thus undermine effective clinical care and policy development [271].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Future Directions > Definitions and diagnostic criteria for clinical obesity
What the sources say
- Not checked yetcites [271] Rubino, 2025, Definition and diagnostic criteria of clinical obesity, Lancet. Diabetes, Endocrinol
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
In the paper
“In controlled trials, RDN-delivered MNT modestly but meaningfully improves dietary quality, body weight, waist circumference, glycemic control, blood pressure, and blood cholesterol levels [[216], [217], [218], [219]].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Behavior Change and Implementation Supports > Registered dietitian nutritionists
What the sources say
- Not checked yetcites [[216], [217], [218], [219]]
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Robust social networks improve health outcomes by reducing stress, increasing motivation, and encouraging accountability [198,199].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Other supportive lifestyle interventions
What the sources say
- Not checked yetcites [198] Lin, 2019, Social network structure is predictive of health and wellness, PLoS One source
- Not checked yetcites [199] Martino, 2017, The connection prescription: using the power of social interactions and the deep desire for connectedness to empower health and wellness, Am. J. Lifestyle Med. source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“In a recent phase 2 randomized trial, 9 wk of low-dose semaglutide in 48 outpatient participants with alcohol use disorder led to reductions in some but not all measures of alcohol use and craving. They led to reductions in tobacco use in the subgroup of current smokers [33].”
§ Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society > Completion of baseline nutritional assessment and screening > Other supportive lifestyle interventions
What the sources say
- Not checked yetcites [33] Hendershot, 2025, Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial, JAMA Psychiatry source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper relies on this without support.
Practical guidance for clinicians to implement a structured lifestyle approach with GLP-1s is limited.
“However, practical guidance for clinicians to implement such an approach is limited.”
The paper relies on this without support.
The potential for more robust, structured nutrition and lifestyle therapy to mitigate weight gain after GLP-1 cessation has not been studied in controlled trials.
“The potential for more robust, structured nutrition and lifestyle therapy to mitigate weight gain after GLP-1 cessation has not been studied in controlled trials.”
The paper relies on this without support.
Population risk and trends in obesity over time are predominantly driven by lifestyle trends related to cultural, community, and environmental factors.
“Although individual risk can be modified by genetic influences, population risk and trends in obesity over time are predominantly driven by lifestyle trends related to cultural, community, and environmental factors.”
The paper relies on this without support.
GI side effects are generally more likely to occur during GLP-1 initiation or dose escalation.
“GI side effects are generally more likely to occur during GLP-1 initiation or dose escalation.”
The paper relies on this without support.
Nausea is the most common GI side effect and often occurs in the morning or after longer periods without eating.
“Nausea is the most common GI side effect and often occurs in the morning or after longer periods without eating.”
The paper relies on this without support.
Constipation is common with weight loss.
“Constipation is common with weight loss and should be managed proactively.”
The paper relies on this without support.
Extended constipation can lead to reactive diarrhea.
“Extended constipation can also lead to reactive diarrhea.”
The paper relies on this without support.
Sarcopenia and osteopenia are seen in individuals who are older, sedentary, chronically ill, malnourished, or with type 2 diabetes.
“Individuals should be assessed for risk of sarcopenia and osteopenia, seen in individuals who are older, sedentary, chronically ill, malnourished, or with type 2 diabetes.”
The paper relies on this without support.
GMVs are covered by insurance payers, allowing broad access.
“GMVs are covered by insurance payers, allowing broad access.”
The paper relies on this without support.
Most individuals prescribed GLP-1s for obesity treatment stop taking the drug within one year.
“While persistent GLP-1 therapy is recommended for obesity control and weight maintenance, most individuals prescribed GLP-1s for obesity treatment stop taking the drug within one year.”
The paper relies on this without support.
Most state Medicaid programs have followed Medicare in limiting MNT coverage.
“Most state Medicaid programs have followed suit.”
The paper relies on this without support.
Commercial plan coverage varies widely and may provide MNT counseling for obesity but with annual or lifetime limits.
“Commercial plan coverage varies more widely and may provide MNT counseling for obesity but with annual or lifetime limits.”
The paper relies on this without support.
Clinicians often lack sufficient knowledge about food, nutrition, and healthy food preparation.
“Clinicians are not immune to these societal trends and often lack sufficient knowledge about food, nutrition, and healthy food preparation.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients accustomed to consuming large volumes of low-energy-density foods are likely to exacerbate GLP-1-induced gastric stasis and postprandial discomfort, supporting a shift toward nutrient-dense, lower-volume feeding patterns during the titration phase [27,33,37].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When a patient receiving a high-dose GLP-1 RA consumes a high-fat meal, the combined effect of pharmacological and endogenous lipid-mediated signaling can produce profound gastric stasis [27,33].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“argues that narrowing this gap will require the systematic integration of Medical Nutrition Therapy (MNT) and structured behavioral support into routine GLP-1 RA care, rather than their continued treatment as optional adjuncts to pharmacotherapy [27].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GI side effects—including nausea, vomiting, bloating, and diarrhea—are profoundly dose-dependent and frequently exacerbated by specific macronutrient profiles [27,33].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The market is characterized by high out-of-pocket costs, complex insurance utilization management, and recurrent supply shortages [27,40,41].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [27]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This dose-dependent increase in toxicity suggests that aggressive titration without concurrent MNT to optimize gastric volume management and meal composition substantially increases the risk of early patient discontinuation [27].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In routine practice, early discontinuation is frequent, with up to 67% of patients ceasing therapy within the first year (Mozaffarian et al., 2025; Alexander et al., 2025).”
From IS OBESITY PHARMACOTHERAPY A LIFETIME COMMITMENT? A STRUCTURED REVIEW OF WEIGHT REGAIN AND STRATEGIES FOLLOWING INCRETIN CESSATION (2026) · cites this paper as Mozaffarian et al., 2025
The cited source says what the claim attributes to it.
In the citing paper
“Resistance exercise has been shown to attenuate the proportion of weight loss composed of lean mass and, together with sufficient protein intake, may be a useful mitigation strategy where there is clinical concern of frailty.”
From The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity (2025) · cites this paper as [27]
The cited source says what the claim attributes to it.
In the citing paper
“The synthesis of global epidemiological data and physiological barriers leads to a clear conclusion: pharmacotherapy alone is unlikely to be sufficient for long-term treatment retention in most patients [27,33].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [27]
The cited source says what the claim attributes to it.
In the citing paper
“Although these agents are now widely prescribed, there remains limited practical guidance or statements on dietary support during treatment [8, 9, 10, 11, 12].”
From Nutrition Strategies for Next‐Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence (2026) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“though recent published guidelines have started to highlight this importance [10]”
From Nutrition Strategies for Next‐Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence (2026) · cites this paper as [10]
In the citing paper
“Despite their therapeutic efficacy, real-world discontinuation rates remain high, 46.5% in people with diabetes and 64.8% in those without, primarily due to high cost,3 and gastrointestinal adverse effects, including nausea, vomiting, diarrhea, gastroparesis, and pancreatitis.3,4”
From Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis (2025) · cites this paper as [4]
In the citing paper
“This pattern aligns with longitudinal findings from the STEP-1 extension and SURMOUNT-4 trials, where body weight increased steadily over 52 weeks of post-treatment follow-up.4,16”
From Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis (2025) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Semaglutide 2.4 mg is described as both daily and weekly
MinorThe efficacy section specifies semaglutide 2.4 mg per day, whereas Table 1 specifies the same dose per week. Those are different dosing frequencies.
“about 8% for individuals with diabetes and 11% for individuals without diabetes at 60 wk with semaglutide 2.4 mg/d [4]”
“| Semaglutide2.4 mg/wk 3 | 14.9% | 2.4% | 12.4% |”
SURMOUNT 3 claim cites a STEP 3 paper
MinorThe cited reference [178] is identified in the reference list as the STEP 3 semaglutide trial, not the SURMOUNT 3 tirzepatide trial used to support the stated 25% reduction.
“whereas in the SURMOUNT 3 trial, tirzepatide 10 or 15 mg/wk started after 12 weeks of intensive lifestyle intervention produced a 25% reduction from baseline (versus 4.8% with intensive lifestyle intervention alone) [178].”
“178. Wadden T.A. Bailey T.S. Billings L.K. Davies M. Frias J.P. Koroleva A. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial”
Table 1 gives a different follow-up time from the text
MinorTable 1 labels its efficacy outcomes as occurring at 52 weeks, while the text describes the outcomes in that table as measured after 56 to 72 weeks.
“TABLE 1 Efficacy and outcomes at 52 wk of GLP-1 therapy1 in the landmark industry-sponsored randomized controlled trials.”
“In the original phase 3 randomized trials for obesity, average weight reduction compared to placebo has ranged from 5.3% to 17.8% after 56 to 72 wk (Table 1)”
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 4×
“Healthfully prepared smoothies and protein drinks with fruits, vegetables, and various unsweetened milks or yogurt; cot-tage cheese and soups can provide needed nutrients and are often more appealing to individuals than heavier foods such as red meats, cold cuts, or hard cheeses.”
InfluentialThe Spread of Obesity in a Large Social Network over 32 Years
Christakis, N. A., & Fowler, J. H. (2007) · New England Journal of Medicine · doi:10.1056/nejmsa066082 · Cited by 5,007 · cited 1×
“Given the network effects of obesity and the added mortality impact of social isolation/loneliness among individuals with obesity, new interventions should be studied to promote social connectivity in conjunction with GLP-1 use [191,192].”
An Ultra-Brief Screening Scale for Anxiety and Depression: The PHQ–4
Kroenke, K., Spitzer, R. L., Williams, J. B. W., & Löwe, B. (2009) · Psychosomatics · doi:10.1016/s0033-3182(09)70864-3 · Cited by 4,261 · cited 1×
“Individuals who report high levels of stress on a Perceived Stress Scale (PSS) 10-item questionnaire [184] or a brief Patient Health Questionnaire for Depression and Anxiety [185] may particularly benefit from stress mitigation interventions.”
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 8×
“…general nutritional instructions produced a 20.9 % reduction in body weight from baseline (versus 3.1 % with general nutrition instructions alone) [15], whereas in the SURMOUNT 3 trial, tirzepatide 10 or 15 mg/wk started after 12 weeks of intensive lifestyle intervention produced a 25 % reduction…”
InfluentialSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · cited 1×
“For example, hemoglobin A1c reduction can occur without weight change, and reduced risk of cardiovascular events appears to emerge before substantial weight reduction [36, 37].”
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
Self-citationA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · cited 4×
“Generally, weight reduction is more rapid during the first 6 months and slows thereafter, with relative plateauing at 18 months [13,15,16].”
InfluentialEffects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403347 · Cited by 2,099 · cited 1×
“…adverse cardiovascular events [23], decreased mortality in heart failure [24 – 28], and improvements in obstructive sleep apnea [12,29], prediabetes [30,31], chronic kidney disease [32], knee osteoarthritis [33], substance use disorders [34], and metabolic-associated steatotic liver disease [35].”
Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates
Sacks, F. M., Bray, G. A., Carey, V. J., Smith, S. R., Ryan, D. H., Anton, S. D., McManus, K., Champagne, C. M., Bishop, L. M., Laranjo, N., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0804748 · Cited by 1,966 · cited 1×
“Various dietary patterns have been used with success, with adherence to counseling visits and the selected diet often being the important factors in determining outcomes [95].”
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914 · cited 1×
“The adverse effects of weight reduction on muscle and bone mass — particularly among individuals with insufficient physical activity or protein intake or at older ages [59,149] — have highlighted the interrelated priorities to preserve muscle mass, muscle quality, bone mass, and physical function.”
Flagged first, then by citations
2 of the 254 references couldn’t be matched to a known paper.
Research works printed but not linked: 9
- 2024, FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, Food and Drug Administration (FDA)
- Atlas, 2023, Medications for obesity management: effectiveness and value, J Manag Care Spec Pharm, 29, 569
- Tondt, 2024, 2024 Obesity Algorithm® E-book, Obes. Med. Assoc.
- Weber, 2024, Ozempic could crush the junk food industry. But it is fighting back, The New York Times Magazine
- Anita, 2024, Group medical appointments for intensive lifestyle treatment for obesity in Cleveland Clinic primary care practices, Patient Cent. Outcomes Res. Inst.
- US Congress. United States Code: Social Security Act, U.S.C. § 1395x: Definitions. From Title 42 -The Public Health and Welfare. Chapter 7-Social Security. Subchapter XVII-Health Insurance for Aged And Disabled. Part E-Miscellaneous Provisions.
- 2024, Proposed rule: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly, Federal Register, United States Government
- 2024, FDA’s Concerns with unapproved GLP-1 drugs used for weight loss, Food and Drug Administration (FDA)
- Radcliffe, 2023, Mounjaro may work better than ozempic for weightloss, study finds
Cited by
Sorted by citations
Items 101–155 of 155
Joshi, S., Misra, A., Mithal, A., Saboo, B., Seshadri, K., Chowdhury, S., Bantwal, G., Sethi, B. K., Kesavadev, J., Bhattacharya, A. D., et al. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100296
“The assessment should include the patient ’ s medical history, including conditions relevant to GBTs, such as gastrointestinal disorders, eating disorders, sarcopenia, renal impairment, weight trajectory, and goals for weight reduction [35].”
InfluentialNguefang, G., Boateng, S., Issaka, Y., Landa, E. L., Gyabaah, S., Mekontso, J. G. K., & Njei, B. M. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08864-2
“GLP-1 RAs suppress appetite and reduce caloric intake by 16% to 39%, levels that may fall below the thresh - olds required to maintain adequate micronutrient consump - tion, particularly for iron, calcium, magnesium, thiamine, vitamin D, and other B vitamins [29, 30 ].”
Babazadeh, D., Zhong, H.-M., & Steinberg, F. M. (2026) · Journal of NutriLife · doi:10.1016/j.tjnut.2026.101753
Geraci, C., Rocca, F. L., Petrina, S. M., Buonauro, A., Morello, V., Paternò, V., Santoro, C., Geraci, G., & Esposito, R. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15155909
“…nutritional assessment, adequate hydration, sufficient protein intake, resistance exercise, symptom-directed pharmacological management, and individualized dietary counseling, as recommended by recent multidisciplinary nutritional guidance and contemporary obesity management algorithms [23,24].”
Rethinking obesity management targets: Findings from an international MoSCoW prioritization workshop
Sockalingam, S., Racey, M., Sherifali, D., Alberga, A. S., Ard, J. D., Horn, D. B., Busetto, L., Kaplan, L. M., le Roux, C. W., Macklin, D., et al. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100311
“The flexibility of the framework would be important as new considerations and components emerge, such as the need for thorough assessment and counselling of patients on GLP-1 RAs [42] and the concept of food noise [43].”
Self-citationRomaniuk, A., Salash, S., Koza, A., Karcz, A., Pająk, B., Bołdys-Żegocki, H., Majewski, J., Kaniecka, M., Dworniczak, M., & Wróblewska, O. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5070
Zajdenverg, L., Santos, V. M., Rodrigues, A. C. M., Previdelli, L. K., & Negrato, C. A. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02235-8
Metabolic Determinants of Weight-Loss Quality During and After Incretin-Based Therapies in Obesity
Luna, M., Rodrigues, B., & Ramalho, A. (2026) · Clinical Nutrition Open Science · doi:10.1016/j.nutos.2026.100711
Zavaleta‐Monestel, E., Arguedas‐Chacón, S., Mora-Jiménez, J., Villalobos-Madríz, J. A., Enríquez-Gutiérrez, B., & Tencio-Morales, K. (2026) · Endocrines · doi:10.3390/endocrines7030044
“These pharmacological differences may influence patterns of exposure and clinical use but cannot be evaluated as mechanistic determinants of the reporting heterogeneity observed in the present study [4].”
Gómez-Maldonado, I., Rodríguez-Arana, A., Tamayo-Pinzón, A., Albornoz-Suárez, J. E., Lopez-Franco, M. J., Mejia-Manrique, J. A., Forero-Caycedo, J. J., Rojas-Rodríguez, L. C., Buitrago-Ricaurte, N., Gaviria-Carrillo, M., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167108
“Accordingly, weight reduction represents the most extensively described therapeutic effect of GLP-1RAs and is considered one of the primary mechanisms through which these agents may improve OSA outcomes [83].”
Choline and metabolic health, a missing link in a critical chain
Paules, E. M. (2026) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000001252
Intensive Behavioral Therapy in an Already Treated Population With Obesity—What Is the Added Value?
Jay, M. R. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.26838
Balasubaramaniam, V., Scobie, M., O’Kane, M. P. M., Graham, Y., Robertson, A. G., & Mahawar, K. K. (2026) · Nutrients · doi:10.3390/nu18162643
“To optimise the use of dietetic expertise, strategies such as risk stratification, group education, digital resources, and escalation criteria may be required [31,52,65].”
InfluentialDiehl, D. L. (2026) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2026.03.030
Ming, Q., & Li, Z. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1914155
He, W., Yi-di, S., Wang, X., He, S.-Y., Tao, X., Yuan, S.-X., Zhou, L., & Long, E.-W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1889594
“Dietary adjustments, including reduced intake of high-fat and high-sugar foods and frequent small meals, may help reduce the incidence and severity of adverse events to some extent (Jastreboff et al., 2022; Wadden et al., 2023; Mozaffarian et al., 2025).”
Sosnowska, M., & Czupryniak, L. (2026) · Endocrines · doi:10.3390/endocrines7030048
“…seeking rapid weight loss—overlaps substantially with the population most likely to use these channels, and commentators have specifically flagged self-directed and weight-loss-motivated use as a setting of elevated risk for misuse and for the precipitation or worsening of disordered eating [25].”
GLP-1 Receptor Agonist Use in Cancer Survivors—Challenges and Opportunities: A Narrative Review
Agurs‐Collins, T., & Sauter, E. R. (2026) · Cancers · doi:10.3390/cancers18162714
“Recognizing these concerns, patients should undergo a comprehensive nutritional assessment prior to initiating GLP-1 medicines to identify existing nutritional risks and facilitate the prompt implementation of appropriate nutrition and metabolic support [60].”
InfluentialVanlaer, Y., de Cauter, E. V., Embo, N., & Benhalima, K. (2026) · BMC Medicine · doi:10.1186/s12916-026-05182-3
Is Nutritional–Behavioral Intervention Effective in the Fight Against Obesity?
Momora, A., Sałacińska, I., Solgajová, A., & Więch, P. (2026) · Nutrients · doi:10.3390/nu18172814
“However, weight regain frequently occurs following discontinuation of GLP-1 receptor agonists, with approximately two-thirds of lost weight typically recovered within one year [42]—a pattern observed even when conventional dietary counseling is provided concurrently [43].”
Medina, N. G., Cui, Y., Chen, D. Q., Fayyaz, M., Xu, F., Mirshafeeyan, M., & Smith, A. M. (2026) · ACS Nano · doi:10.1021/acsnano.6c00432
Ernährungsintervention zur Therapie der Adipositas
Zumblick, A., & Kabisch, S. (2026) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2892-0913
“Durch die dadurch verringerte Nahrungsaufnahme kann die Behandlung mit GLP-1-RA zu einem Nährstoffmangel sowie Muskel-und Knochenverlust führen [57].”
InfluentialHoughton, M. J., Peiris, D. R., Sulaimani, N., Visvanathan, R., Nicolotti, L., & Cardoso, B. R. (2026) · Food & Function · doi:10.1039/d6fo02120d
Buciuc, A. G., Gold, M. S., & Fuehrlein, B. (2026) · Addiction & Prevention · doi:10.3390/addictprev1010007
The Evolution of Medications for Obesity Management
Gill, J., & Sumithran, P. (2026) · JGH Open · doi:10.1002/jgh3.70466
Digital health, technology, AI, and wearables in obesity care
Hallock, R., Cabandugama, P. K., & Patel, N. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.06.004
Caturano, A., Mocini, E., Titi, L., Leva, F., Cannavaro, D., Tarsitano, M. G., & Conte, C. (2026) · Nutrients · doi:10.3390/nu18172933
“Similar attention to protein intake, nutrient density, resistance exercise, and muscle-function monitoring is recommended for patients receiving incretin-based therapy [93,94].”
Patient characteristics and early experiences with anti-obesity medications: the CAMP study
Tewksbury, C. M., Soliva, E. A., Scheffey, K., Kwong, P. L., & Glanz, K. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1931188
Cautela, D., Valeria, I., Lombardi, A., Laratta, B., Castaldo, C. M., Balestrieri, M. L., Mocini, E., Migliaccio, S., & Tardito, D. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188057
“Protein intake and resistance exercise should be individualized according to age, frailty, habitual activity, comorbidities, and renal function [109].”
Digital Health in Obesity Care: Current Evidence, Challenges, and Future Directions
Pagoto, S., & Bannor, R. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00757-w · Cited by 1
GIORGIO, C. M., Romanò, C., Arisi, M., Rossi, M., Venturini, M., Mezzana, S., Grigolato, L., Gallì, B., Nicoletti, M. M., Tomasi, C., et al. (2026) · Dermatology and Therapy · doi:10.1007/s13555-026-01916-6
“Although these findings require confirmation in human tissue, they indicate that the regenerative properties of GLP-1RAs may extend beyond their endocrine actions [15].”
InfluentialHemodynamic-Guided Nutrition Support in Pediatric Congenital Heart Disease
Pandey, A., Varayil, J. E., Fleishman, C. E., & Sankararaman, S. (2026) · Current Nutrition Reports · doi:10.1007/s13668-026-00802-z
“Lean mass preservation is a relevant consideration in pediatric GLP-1 RA use [86 ] and based on adult evidence, clinicians should pair pharmacotherapy with resistance training and adequate protein intake [87].”
Makri, R., Evangelou, I., Karaglani, E., Vlachava, M., Dafoulas, G., Drympeta, I., Votis, K., Georga, E. I., Fotiadis, D. I., Lupiáñez‐Villanueva, F., et al. (2026) · Obesity · doi:10.1002/oby.70284
Yetgin, M. K., Gletsu-Miller, N. A., Chapman, R. F., Gelber, E., Snyder, J., Gregg, D., & Nabhan, D. C. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100335
“Nutritional guidance was individualized for each participant, with protein intake recommended to be obtained primarily from whole-food sources rather than supplements, including lean fish, seafood, poultry, dairy products, and legumes [14].”
InfluentialRatanpaul, V. (2026) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2026.101535
Eighty Years After Vague: Advances in Understanding Ectopic Fat and Metabolic Dysfunction
Conte, C., Sumithran, P., le Roux, C. W., Miras, A. D., & Gaal, L. V. (2026) · Obesity Reviews · doi:10.1111/obr.70229
Lifestyle Modification and Incretin Therapy for Individuals With Obesity
Glatter, R., & Luciani, E. (2026) · JAMA · doi:10.1001/jama.2026.14697
Shimizu, M. A., Oliveira, M. R., Teixeira, J. M., Gerolamo, A. C. S., & Queiroz, M. M. D. G. (2026) · Brazilian Journal of Medical and Health Sciences · doi:10.64597/eb91a803
Gupta, S. D., Loubeau, J. K., Priyanka, A. S., Tineo, Y. A. C., Diaz‐Martinez, J., Sánchez, M., & Agarwal, R. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100338
“Beyond individual insurance plans, broader coverage instability has also been documented at the state level, with some Medicaid programs dropping GLP-1 coverage due to high costs and unsuccessful pricing negotiations [43].”
Incretin-Based Therapies and the Associated Impact on Bone Health
Łupina, K., Bronowski, M., Dardzińska, N., Jaskulska, P., Nowak, A., Romac, A., RÓŻAŃSKI, P., & Janczura, J. (2026) · International Journal of Pharmacology · doi:10.31083/ijp53550
Hu, F. B., Beleslin, B., Blaha, M. J., Kris-Etherton, P. M., Seligman, H. K., & Williams, K. A. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.08.025
Chaturvedi, R., Singh, K., Chakole, R., Yadav, B. K., Dhameliya, J., & Joshi, D. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1969433 · Cited by 1
“…resistance training to attenuate lean mass loss during caloric restriction (29 – 31); screening for micronutrient de fi ciencies (iron, B12, vitamin D) in patients with prolonged appetite suppression; and sarcopenia risk assessment (e.g., SARC-F, grip strength, gait speed) in older adults (10, 28).”
Brahmbhatt, S., Mathew, A., Shoap, S. C., & Kumar, A. (2026) · HSS Journal® The Musculoskeletal Journal of Hospital for Special Surgery · doi:10.1177/15563316261492267
“12,13 Unlike bariatric surgery, GLP-1 RAs do not impair nutrient absorption, but reduced food intake may lead to insufficient intake of nutri-ents such as iron, calcium, and vitamins, especially when daily caloric intake is less than 1200 kcal.”
Current Evidence and Practical Considerations for GLP-1 Receptor Agonists in Gynecologic Oncology
Neveu, J., Mateo-Kubach, P., Pervan, M., Meschini, T., Sabini, C., Martínez, Z. R. M., Loverro, M., Maureen, B., Villagrá, I., Del, M., et al. (2026) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2026.105660 · Cited by 1
Yacaman, G. J. P., López, A. M. J., Cordova, P. R., Cuenca, S. E. A., López, S. M., Lladó, A. I. C., Quintero, D. O. B., Bárcena, E. D. C., Mottú, R. A. Z., Flores, V. Z., et al. (2026) · Cureus · doi:10.7759/cureus.117774
Fabre, O., Bailly, S., Pantagis, L., Legrand, R., Lean, M. E. J., Gaal, L. F. V., Jebb, S. A., & Astrup, A. (2026) · Nutrients · doi:10.3390/nu18203364
“Adequate protein intake and regular physical activity have been emphasized in recent expert recommendations as important supportive measures during GLP-1 RA treatment, particularly to help preserve lean body mass [20–22].”
Incretin-based therapies in menopause: Current landscape
Castaneda, R., Pavlov, K., Shufelt, C. L., & Faubion, S. S. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.109159
Patoulias, D., Popovic, D. S., & Koufakis, T. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71445
Schwartzberg, E., Azran, C., Diker‐Cohen, T., Shani, S., & Dotan, I. (2026) · Exploratory Research in Clinical and Social Pharmacy · doi:10.1016/j.rcsop.2026.100867
GLP‐1 Receptor Agonists and Cancer Risk in Obesity Treatment
Hofseth, L. J., Murphy, E. A., Playdon, M. C., Makowski, L., Ibele, A. R., Fairman, C. M., & Hébert, J. R. (2026) · Obesity Reviews · doi:10.1111/obr.70247
Future directions in obesity pharmacotherapy: Novel targets and pipeline therapies
Mauer, Y., & Isaacs, D. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.06.003
Pharmacist-Led Medication Titration for Cardiometabolic Disease: Evidence, Equity, and Scale
Yarlagadda, S., & Blood, A. J. (2026) · Current Cardiology Reports · doi:10.1007/s11886-026-02432-x
Macesic, M. V., Radovic, F., Zeković, J., Simić, A., Skrobić, O., Stepanovic, B., Nestorov, J. M., Popovic, J., Bursic-Vukadin, M., & Djuranovic, A. (2026) · Sports · doi:10.3390/sports14110473
Digital Food Purchase Signatures and Their Response to GLP‐1‐Based Treatment in People With Obesity
Orban, F., Cerro, L. F., Stoll, M., Rupp, M. E., Herzig, D., & Bally, L. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71494
Schwartzberg, E., Berman, E., Shani, S., Azran, C., Hagoel, R., Diker‐Cohen, T., & Dotan, I. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2756017
Metadata
- Authors
- Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., Gulati, M., Gupta, A., Horn, D., Kane, R. M., Saluja, J., Sannidhi, D., Stanford, F. C., & Callahan, E. A.
- Affiliations
- Tufts University (US)
- University of Alabama at Birmingham (US)
- University of Florida Health (US)
- Brigham and Women's Hospital (US)
- Stanford Medicine (US)
- Cleveland Clinic (US)
- Lenox Hill Hospital (US)
- UConn Health (US)
- George Washington University (US)
- The University of Texas at Austin (US)
- Duke University (US)
- University of California San Diego (US)
- Harvard University (US)
- Corresponding author
- Mozaffarian, Dariush
- ORCID
- Venue
- The American Journal of Clinical Nutrition
- Publisher
- Elsevier BV
- Published
- 2025-07
- Volume
- 122
- Issue
- 1
- Pages
- 344-367
- ISSN
- 0002-9165 (ISSN-L)
- PMC
- PMC12612741
- OpenAlex
- W4410885131
- Cited by
- 154
- References
- 254
- Citations by year
- 2026: 128 · 2025: 26
- FWCI
- 86.51
- Type
- journal article
- Language
- en
- Update notices
- Open access
- hybrid
- doi.org
- Licence
- Locations
- American Journal of Clinical Nutrition (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Suomen Kardiologinen Seura
- National Institutes of Health (2R01 HL115189, P30 DK04056, UE5 DK137285, U24 DK132733)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- obesity treatment, dietary intervention, lifestyle intervention, weight management, gastrointestinal adverse effects, nutritional deficiency, weight regain, adherence, food as medicine, social determinants of health, nutritional insecurity, telemedicine, resistance training, cost-effectiveness
- MeSH terms
- Humans, Life Style, Obesity, United States, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
